- Home
- NZF vs LGND Comparison
NZF vs LGND Comparison
Compare NZF & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NZF
- LGND
- Stock Information
- Founded
- NZF 2001
- LGND 1987
- Country
- NZF United States
- LGND United States
- Employees
- NZF N/A
- LGND N/A
- Industry
- NZF Finance Companies
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- NZF Finance
- LGND Health Care
- Exchange
- NZF Nasdaq
- LGND Nasdaq
- Market Cap
- NZF 2.2B
- LGND 2.1B
- IPO Year
- NZF N/A
- LGND 1992
- Fundamental
- Price
- NZF $12.03
- LGND $104.48
- Analyst Decision
- NZF
- LGND Strong Buy
- Analyst Count
- NZF 0
- LGND 8
- Target Price
- NZF N/A
- LGND $144.71
- AVG Volume (30 Days)
- NZF 496.8K
- LGND 102.0K
- Earning Date
- NZF 01-01-0001
- LGND 05-08-2025
- Dividend Yield
- NZF 4.67%
- LGND N/A
- EPS Growth
- NZF N/A
- LGND N/A
- EPS
- NZF N/A
- LGND N/A
- Revenue
- NZF N/A
- LGND $181,488,000.00
- Revenue This Year
- NZF N/A
- LGND $16.47
- Revenue Next Year
- NZF N/A
- LGND $19.44
- P/E Ratio
- NZF N/A
- LGND N/A
- Revenue Growth
- NZF N/A
- LGND 53.40
- 52 Week Low
- NZF $9.82
- LGND $72.61
- 52 Week High
- NZF $12.29
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- NZF 56.71
- LGND 46.11
- Support Level
- NZF $11.93
- LGND $99.24
- Resistance Level
- NZF $12.06
- LGND $107.37
- Average True Range (ATR)
- NZF 0.09
- LGND 4.05
- MACD
- NZF 0.05
- LGND -0.33
- Stochastic Oscillator
- NZF 94.53
- LGND 39.37
About NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.